

## DAFTAR PUSTAKA

- Abramowitz, M. K. *et al.* (2013). *Effects of oral sodium bicarbonate in patients with CKD*. Clinical Journal of the American Society of Nephrology.
- Akbar, R., Setyaningrum, N. and Estiningsih, D. (2017) *.Kajian Penggunaan Obat Off-Label pada Anak di Puskesmas Sleman*. INPHARNMED:Journal (Indonesian Pharmacy and Natural Medicine Journal).
- Alten, R. and Maleitzke, T. (2013). *Tocilizumab: A novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases*. Annals of Medicine.
- Anan, F. *et al.* (2006). *Hyperhomocysteinemia is a significant risk factor for silent cerebral infarction in patients with chronic renal failure undergoing hemodialysis*. Metabolism: Clinical and Experimental.
- Argolini, L. M. *et al.* (2020). *Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up*. Journal of Nephrology:Springer International Publishing.
- Ariati, A. L., Kartinah, N. and Intannia, D. (2015). *Gambaran Penggunaan Obat Off-Label Pada Pasien Pediatrik Rawat Jalan Di RSUD Ulin Banjarmasin Periode Januari-Desember 2013*.Jurnal Pharmascience
- ASHP (2003). *ASHP statement on the role of health-system pharmacists in public health*. American Journal of Health-System Pharmacy
- Bamonti-Catena, F. *et al.*(1999). *Folate measurements in patients on regular hemodialysis treatment*. American Journal of Kidney Diseases
- Blikman, T. *et al.* (2016). *Duloxetine in osteoarthritis (DOA) study: Study protocol of a pragmatic open-label randomised controlled trial assessing the effect of preoperative pain treatment on postoperative outcome after total hip or knee arthroplasty*. BMJ Open
- Blom & Smulders (2011). *Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects*. Journal of Inherited Metabolic Disease.
- Bompas, E. (2007). *Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year : The French Sarcoma Group*.Journal Of Clinical Oncology
- Bostom, A. G. *et al.* (2000). *Controlled comparison of L-5-methyltetrahydrofolate*

*versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients.* Circulation.

Branley, P. (2006). *Use of phosphate binders in chronic kidney disease.* Nephrology.

Bravo-Soto, G. A. and Madrid, T. (2016). *Is folic acid supplementation useful for chronic kidney disease?.* Medwave

De Brito-Ashurst, I. *et al.* (2009). *Bicarbonate supplementation slows progression of CKD and improves nutritional status.* Journal of the American Society of Nephrology.

Capelli, I. *et al.* (2019). *Folic acid and vitamin B12 administration in CKD, why not?.* Nutrients

Cersosimo, E. *et al.* (2014). *Assessment of Pancreatic-Cell Function: Review of Methods and Clinical Applications.* Current Diabetes Reviews

Chahal, H. and World Health Organization (2014). *Section 3 : Antiallergics and Medicines Used in Anaphylaxis.* The Selection and Use of Essential Medicines

Chan, S. *et al.* (2017). *Phosphate binders in patients with chronic kidney disease.* Australian Prescriber

Cianciolo, G. *et al.* (2008). *5-Methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients.* American Journal of Nephrology.

Cianciolo, G. *et al.* (2017). *Folic acid and homocysteine in chronic kidney disease and cardiovascular disease progression: Which comes first?.* CardioRenal Medicine.

Cruz-Pérez, F. *et al.* (2018). *Efficacy of Cyclosporine in the Induction and Maintenance of Remission in a Systemic Lupus Erythematosus Patient Presenting with Macrophage-Activating Syndrome.* Case Reports in Rheumatology.

DA, S. (2002) *Penggunaan Asam Folat pada Gagal Ginjal Kronik.* Fakultas Kedokteran UGM.

Danés, I. *et al.* (2014). *Outcomes of off-label drug uses in hospitals: A multicentric prospective study.* European Journal of Clinical Pharmacology.

Daniel E Shumer Norman P Spack, N. J. N. (2017). *Oral calcium carbonate affects calcium but not phosphorus balance in stage 3–4 chronic kidney disease.* Physiology & behavior

Darmaja, I Made Gede . Suwitra, K. (2006). *Perbandingan Efektifitas Asam Folat*

- Davis, J. (2008). *Eculizumab*. American Journal of Health-System Pharmacy
- Dębowska, M. and Przedlacki, J. (2017). *Treatment of metabolic acidosis in patients with chronic kidney disease (CKD)*. Wiadomosci lekarskie (Warsaw, Poland).
- Ding, H. J. and Gordon, C. (2013). *New biologic therapy for systemic lupus erythematosus*. Current Opinion in Pharmacology: Elsevier Ltd.
- Dipiro (2001). *Pharmacotherapy A Pathophysiologic Approach Seventh Edition*. MC Graw Hill Medical
- Rusli (2018). *Buku Ajar Farmasi Klinik*(1st edn). Kementrian Kesehatan Republik Indonesia
- Eguale, T. *et al.* (2016). *Association of off-label drug use and adverse drug events in an adult population*. JAMA Internal Medicine.
- Emadi, A., Jones, R. J. and Brodsky, R. A. (2009). *Review Cyclophosphamide and cancer: golden anniversary*. Nature Reviews Clinical Oncology:Nature Publishing Group.
- Eschbach, J. *et al.* (2001). *IV NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000*. American Journal of Kidney Diseases
- Family Physician, A., Joyce Hollander rodriguez, H. C. and Calvert, J. F. (2006) . *Hyperkalemia*. American Family Physician.
- Fauzi, A. *et al.* (2016). Nefrolitiasis.
- Fisher, K. and Hanspal, R. S. (1998). *Lowering blood homocysteine with folic acid basedsupplements: meta#analysis of randomised trials*. British Medical Journal.
- Flanc, R. S. *et al.* (2004). *Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials*. American journal of kidney diseases : the official journal of the National Kidney Foundation.
- Friedman, A. N. *et al.* (2001). *The kidney and homocysteine metabolism*. Journal of the American Society of Nephrology.
- Gang Jee Ko, MD, PhD1, 2, Yoshitsugu Obi, MD, PhD1, Amanda R. Tortoricci, RD1, and Kamyar Kalantar-Zadeh, MD, MPH, P. (2017). *Dietary Protein Intake and Chronic Kidney Disease*. Physiology & behavior

- Generali, J. A. and Cada, D. J. (2014). *Off-Label Drug Uses - Atorvastatin : Rheumatoid Arthritis*.
- Generali, J. A. and Cada, D. J. (2016). *Benazepril: Nephropathy (non-diabetic)*. Hospital Pharmacy.
- Generali, J., Cada, D. J. and Editor, F. (2008). *Off-Label Drug Uses Rasburicase : Gout*.
- Gordon H, Guyatt; D oxman, Andrew; e Vist, G. (2008). *GRADE: an emerging consensus on rating quality of evidence and strength of recommendations*. BMJ (Online).
- Gunnarsson, I. and Jonsdottir, T. (2013). *Rituximab treatment in lupus nephritis - Where do we stand?*. Lupus.
- Hidayati, N. R. (2019). *Skrining Penggunaan Obat Off Label Pada Pasien Obstetri Dan Ginekologi Di Rumah Sakit Daerah Gunung Jati Cirebon*. Journal of Pharmacopolium.
- Hill, K. M. *et al.* (2013). *Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease*. *Kidney International*. Nature Publishing Group
- Hillmen, P. *et al.* (2006). *The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria*. *New England Journal of Medicine*.
- Hirnerova, E. *et al.* (2003). *Effect of vitamin E therapy on progression of diabetic nephropathy*. *Vnitr Lek*.
- Hirsh, R. *et al.* (2009). *Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria*. *American Journal of Hematology*
- Howard A. *et al.* (1986). *Therapy Of Lupus Nephritis*.
- Huo, Y. *et al.* (2015). *Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: The CSPPT randomized clinical trial*. *JAMA - Journal of the American Medical Association*.
- Indonesia, P. R. (2011). *Rekomendasi Perhimpunan Reumatologi Indonesia Untuk Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik*. ISBN
- Di Iorio, B. R. *et al.* (2019). *Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study*. *Journal of Nephrology*.
- Jafar et al (2003). *Article Progression of Chronic Kidney Disease : The Role of Blood Pressure*.

- Jeremiah, T. *et al.* (1997). *Controlled Comparison of L-Folinic Acid Versus Folic Acid for the Treatment of Hyperhomocysteinemia in Hemodialysis Patients.*
- Journal, O. *et al.* (2012). *Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Acute Kidney Injury.*
- K. Krüger, München J. Sieper, B. (2011). *Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects* Kalantar-Zadeh, K. *et al.* (2004). *A Low, Rather than a High, Total Plasma Homocysteine Is an Indicator of Poor Outcome in Hemodialysis Patients.* Journal of the American Society of Nephrology.
- Kang, S., Wong, P. W. K. and Malinow, M. R. (1992). *Hyperhomocysteinemia As A Risk Factor For Occlusive Vascular Disease.* National Heart, Lung and Blood Institute (HL).
- Kazama, J. J. (2009). *Oral phosphate binders: History and prospects.* Bone. Elsevier.
- KDIGO (2013). *Chapter 3: Management of progression and complications of CKD.* Kidney International Supplements.
- Kemenkes (2012) *Formularium Spesialistik Ilmu Penyakit Dalam.* Jakarta.
- KHODIJAH, S. (2016) *Identifikasi Peresepan Obat Off-Label Indikasi Pada Pasien Dewasa Rawat Inap Di Rumah Sakit PKU Muhammadiyah Yogyakarta Periode Januari - Desember 2014.*
- Kilmer, P. D. (2010). *Review Article: Review Article.* Journalism: Theory, Practice & Criticism.
- Klein, D. B. and Tabarrok, A. (2004). *Who Certifies Off-Label?.* Regulation
- Knight, D. (2005). *Higher versus Lower Positive End-Expiratory Pressures in Patients with the Acute Respiratory Distress Syndrome.* Journal of the Intensive Care Society.
- Koski, R. R. and Zufall, W. H. (2018). *Efficacy and Safety of Alpha-Blockers for Kidney Stones in Adults.* Journal of Pharmacy Technology.
- Kovesdy, C. P., Anderson, J. E. and Kalantar-Zadeh, K. (2009). *Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD.* Nephrology Dialysis Transplantation.
- Koyama, K. *et al.* (2002). *Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation.* Nephrology Dialysis Transplantation.
- Kuller, L. H., & Evans, R. W. (2015). *Homocysteine, Vitamins, and Cardiovascular*

*Disease.*

- Kunz, K. *et al.* (1999). *Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: Is homocysteine the missing link?*. Nephrology Dialysis Transplantation
- Lee, S. J., Silverman, E. and Bargman, J. M. (2011). *The role of antimalarial agents in the treatment of SLE and lupus nephritis*. Nature Reviews Nephrology: Nature Publishing Group.
- Lieberman, J. A. and Chehade, M. (2013). *Use of omalizumab in the treatment of food allergy and anaphylaxis*. Current Allergy and Asthma Reports.
- Lin, H. W., Phan, K. and Lin, S. J. (2006). *Trends in off-label  $\beta$ -blocker use: A secondary data analysis*. Clinical Therapeutics.
- Little RE, S. C. (2013). *Calcium Carbonate as a Phosphate Binder in Patients with Chronic Renal Failure Undergoing Dialysis*. the new england journal of medicine.
- Long, Y. and Nie, J. (2016). *Homocysteine in Renal Injury*. Kidney Disease
- Łoniewski, I. and Wesson, D. E. (2014). *Bicarbonate therapy for prevention of chronic kidney disease progression*. Kidney International:Elsevier Masson SAS.
- Mallamaci, F. *et al.* (2002). *Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients*. Kidney International.
- Mayes PA, B. K. (2007) *Harper's Review of Biochemistry. 26th edn, Military Medicine. 26th edn*. New York: Mac Graw Hill.
- McEvoy, T. (2016). *Minocycline: Rheumatoid arthritis*. Hospital Pharmacy.
- Michael Belmont, H. (2013). *Treatment of systemic lupus erythematosus: 2013 update*. Bulletin of the Hospital for Joint Diseases.
- Moe, S. M., Veterans, R. and Medical, A. (2018). *Calcium and phosphate balance in CKD*.
- Mok, C. C. *et al.* (2004). *Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis*. Arthritis and Rheumatism.
- Moroni, G., Doria, A. and Ponticelli, C. (2009). *Cyclosporine (CsA) in lupus nephritis: Assessing the evidence*. Nephrology Dialysis Transplantation.
- Mulyani, U. A. (2018). *Should Off-Label Medicines Be Included In The Universal Health Coverage (UHC) Schemes? Why, When, and How?*. Jurnal Penelitian

dan Pengembangan Pelayanan Kesehatan.

- Murti, P. B. (2005). *Pengantar Evidence-Based Medicine*.
- Naesens, M., Kuypers, D. R. J. and Sarwal, M. (2009). *Calcineurin inhibitor nephrotoxicity*. Clinical Journal of the American Society of Nephrology.
- Navaneethan, S. D. *et al.* (2009). *Phosphate binders for preventing and treating bone disease in chronic kidney disease patients*. Cochrane Database of Systematic Reviews.
- Navaneethan, S. D. *et al.* (2011). *Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease*. Clinical Journal of the American Society of Nephrology.
- Nerbass, F. B., Draibe, S. A. and Cuppari, L. (2005). *Hyperhomocysteinemia in chronic renal failure*. Revista de Nutricao.
- Neto, R. and Frazão, J. (2019). *Efficacy and safety of calcium carbonate in normophosphataemic patients with chronic kidney disease Stages 3 and 4*. Clinical Kidney Journal.
- Nugroho, M. B. (2019). *Profil Penggunaan Obat Off-Label pada Pasien Anak Rawat Inap di Rumah Sakit Umum Daerah (RSUD) Dr. Saiful Anwar Malang Tahun 2018*. Journal of Chemical Information and Modeling.
- Obeid, R. *et al.* (2005). *Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients*. Clinical Chemistry.
- Ogawa, H. *et al.* (2010). *Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice*. Lupus.
- Palestine, A. G., Nussenblatt, R. B. and Chan, C. C. (1984). *Side effects of systemic cyclosporine in patients not undergoing transplantation*. The American Journal of Medicine.
- Parham, W. A. *et al.* (2006). *Hyperkalemia revisited*. Texas Heart Institute Journal.
- PATH (2017). *Review of Laws , Regulations , and Uses of Off-label Drugs in Indonesia*.
- Patkar, A. *et al.* (2007). *Off-label prescribing of erythropoiesis-stimulating proteins in US hospitals*. Drug Information Journal.
- Permenkes RI (2008). *Tentang Rekam Medis*. Permenkes RI No 269/MenKes/Per/III/2008.
- Piers *et al* (2009). *Chronic Kidney Disease*. The Lancet.

- Ponticelli, C. (2005). *Cyclosporine: From renal transplantation to autoimmune diseases*. Annals of the New York Academy of Sciences.
- Pratiwi, E. A. (2015). *Penggunaan obat off label pada pasien hamil di instalasi rawat inap dan gawat darurat kebidanan kandungan RSUP Fatmawati periode Maret 2015*.
- Pringgodigdo Nugroho, M. (2018). *The Effectiveness and Safety of Calcium Carbonate in Chronic Kidney Disease With Normophosphatemia*, Indonesia University.
- Qin, X. et al. (2011). *Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: A meta-analysis*. Clinical Journal of the American Society of Nephrology.
- Radhakrishnan, J. et al. (1995). *Use of cyclosporin in lupus nephritis*. Contributions to nephrology.
- Radley, D. C., Finkelstein, S. N. and Stafford, R. S. (2006). *Off-label prescribing among office-based physicians*. Archives of Internal Medicine.
- Rahajeng, B. (2019). *Kajian Risiko - Manfaat Penggunaan Antikonvulsan Secara Off-Label pada Terapi Nyeri Neuropati Sentral Post Stroke Studi pada Pregabalin dan Gabapentin*.
- Rahman, Q. (2011). *Ameliorative Effects of Dimethylthiourea and N-Acetylcysteine on Nanoparticles Induced Cyto-Genotoxicity in Human Lung Cancer Cells-A549*.
- Randaccio, L. et al. (2010). *Vitamin B12: Unique metalorganic compounds and the most complex vitamins*. Molecules.
- Raphael, K. L. (2016). *Approach to the treatment of chronic metabolic acidosis in CKD*. American Journal of Kidney Diseases:Elsevier Inc.
- Riddell, L. J. et al. (2000). *Dietary strategies for lowering homocysteine concentrations*. American Journal of Clinical Nutrition.
- Righetti, M. et al. (2006). *Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients*. Blood Purification.
- Riou, S. et al. (2015). *Unlicensed and off-label drug use: A prospective study in French NICU*. Acta Paediatrica:International Journal of Paediatrics.
- Riskesdas, K. (2017). *InfoDATIN Pusat Data dan Informasi Kementerian Kesehatan RI: Situasi Penyakit Ginjal Kronis*. Depkes RI
- Rivard, R. (2015). *Tamsulosin: Ureteral Stones (Distal)*.Hospital Pharmacy.

- Robak, E. and Robak, T. (2009). *Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus*. Current Drug Targets.
- RSUD Prof. Dr. Margono Soekarjo (2019). *10 Besar Kasus Rawat Inap SMF Penyakit Dalam di RSMS RSUD Margono Soekarjo 2018*. RSUD Prof. Dr. Margono Soekarjo.
- Rtega, V. I. O. and Ar, M. (2004). *Calcium citrate ameliorates the progression of chronic renal injury*. Nephron.
- Sackett DL, Rosenberg WM, Gray JA, Haynes RB, R. W. (1996). *Evidence based medicine: what it is and what it isn't*. BMJ (Online).
- Samuel *et al.* (2017). *Phosphate binders in patients with chronic kidney disease*.
- Schaefer, R. M. (2002). *Folate metabolism in renal failure*. Nephrology Dialysis Transplantation.
- Schioppo, T. and Ingegnoli, F. (2017). *Current perspective on rituximab in rheumatic diseases*. Drug Design:Development and Therapy.
- Sekercioglu, N. *et al.* (2020). *Comparative effectiveness of phosphate binders in patients with chronic kidney disease: A systematic review and network meta-analysis*. PLoS ONE.
- Setyani, D. S. *et al.* (2018). *Analysis of High Dose and Long-Term Prednisone Therapy on Trap 5B Level Change in Children with Steroid Sensitive Nephrotic Syndrome*. Folia Medica Indonesiana.
- Setyaningrum, N., Gredynadita, V. and Gartina, S. (2017). *Penggunaan Obat Off-Label pada Anak di Apotek Kota Yogyakarta*. Jurnal Sains Farmasi & Klinis.
- Shimizu (2005). *N-acetylcysteine attenuates the progression of chronic renal failure*.
- Shirota, Y. *et al.* (2013). *Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus*. Annals of the Rheumatic Diseases.
- Singh, J. A. *et al.* (2016). *Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: A systematic review and network meta-analysis*.
- Snaith, M. L. *et al.* (1981). *Cyclosporin a for the treatment of systemic lupus erythematosus*.
- Soedarto (2012) *Alergi dan Penyakit Sistem Imun*. Jakarta.
- Soofoo, M. *et al.* (2017). *Association of serum vitamin B12 and folate with*

- mortality in incident hemodialysis patients. *Nephrology Dialysis Transplantation*.
- Stafford, R. S. (2008). *Regulating off-label drug use - Rethinking the role of the FDA*. *New England Journal of Medicine*.
- Suhartina Hamzah, Marianti A. Manggau, N. A. (2017). *Analisis Efektifitas Dan Efek Samping Penggunaan Off-Label Rute Pemberian Dari Nifedipine Sebagai*.
- Tabarrok, A. (2000). *Assessing the FDA Via the Anomaly of Off-Label Drug Prescribing*. Independent Review.
- The Australasian Society of Clinical Immunology and Allergy (ASCIA) (2015) *Anafilaksis ( Anaphylaxis )*.
- Tokuda, M. *et al.* (1994). *Effect of low-dose cyclosporin a on systemic lupus erythematosus disease activity*. *Arthritis & Rheumatism*.
- Toohy, J. I. (2017). *Possible involvement of hydrosulfide in B12-dependent methyl group transfer*. *Molecules*.
- Tri, R. *et al.* (2015). *Pengaruh Pemberian N-Acetylcysteine Oral terhadap High Sensitivity C Reactive Protein ( Hs-CRP ) pada Pasien Hemodialisis Kronis*.
- Tuominen, T. *et al.* (2002) *K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification*. *Annales Chirurgiae et Gynaecologiae*.
- Tzu *et al.* (2018). *Cyclosporine for the treatment of lupus nephritis in patients with systemic lupus erythematosus*.
- Wald, D. S. *et al.* (2001). *Randomized trial of folic acid supplementation and serum homocysteine levels*. *Archives of Internal Medicine*.
- Wallace, D. J. (2007) *The lupus book*. *Annals of the Rheumatic Diseases*.
- Wistiani, *et al* (2011). *Hubungan Paparan Alergen Terhadap Kejadian Alergi pada Anak*.
- Wuryana, D., Suryana, B. P. and Yulistiani, Y. (2016). *Effectivity and Renal Safety of Cyclosporine and Methylprednisolone Combination Therapy in Patients With Systemic Lupus Erythematosus (Sle)*. *Folia Medica Indonesiana*.
- Xu, X. *et al.* (2016). *Efficacy of folic acid therapy on the progression of chronic kidney disease: The renal substudy of the China stroke primary prevention trial*. *JAMA Internal Medicine*.
- Ye, Z. *et al.* (2016). *High prevalence of hyperhomocysteinemia and its association*

*with target organ damage in chinese patients with chronic kidney disease. Nutrients.*

Yongsiri, S. *et al.* (2015). *Randomized, Double-Blind, Placebo-Controlled Trial of Spironolactone for Hypokalemia in Continuous Ambulatory Peritoneal Dialysis Patients.* Therapeutic Apheresis and Dialysis.

Zoungas, S. *et al.* (2006). *Cardiovascular Morbidity and Mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: A multicenter, randomized, controlled trial.* Journal of the American College of Cardiology.

